EA202192923A1 - Антитела и способы лечения инфекции, вызываемой вирусом гриппа а - Google Patents
Антитела и способы лечения инфекции, вызываемой вирусом гриппа аInfo
- Publication number
- EA202192923A1 EA202192923A1 EA202192923A EA202192923A EA202192923A1 EA 202192923 A1 EA202192923 A1 EA 202192923A1 EA 202192923 A EA202192923 A EA 202192923A EA 202192923 A EA202192923 A EA 202192923A EA 202192923 A1 EA202192923 A1 EA 202192923A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antibodies
- influenza
- treatment
- virus infection
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2019/061134 WO2020221450A1 (en) | 2019-04-30 | 2019-04-30 | Antibodies and methods for treatment of influenza a infection |
| PCT/EP2020/062160 WO2020221908A1 (en) | 2019-04-30 | 2020-04-30 | Antibodies and methods for treatment of influenza a infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202192923A1 true EA202192923A1 (ru) | 2022-02-16 |
Family
ID=66429359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202192923A EA202192923A1 (ru) | 2019-04-30 | 2020-04-30 | Антитела и способы лечения инфекции, вызываемой вирусом гриппа а |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20220226470A1 (https=) |
| EP (1) | EP3962530A1 (https=) |
| JP (1) | JP7719725B2 (https=) |
| KR (1) | KR20220003000A (https=) |
| CN (2) | CN114269381A (https=) |
| AU (1) | AU2020265407B2 (https=) |
| BR (1) | BR112021018409A2 (https=) |
| CA (1) | CA3132536A1 (https=) |
| CL (1) | CL2021002807A1 (https=) |
| CO (1) | CO2021012583A2 (https=) |
| EA (1) | EA202192923A1 (https=) |
| IL (1) | IL287423A (https=) |
| MX (1) | MX2021012984A (https=) |
| PH (1) | PH12021552176A1 (https=) |
| SG (1) | SG11202109683TA (https=) |
| TW (1) | TW202106707A (https=) |
| WO (2) | WO2020221450A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102820941B1 (ko) | 2018-01-26 | 2025-06-16 | 리제너론 파마슈티칼스 인코포레이티드 | 인플루엔자 헤마글루티닌에 대한 인간 항체 |
| IL290752B2 (en) * | 2019-08-29 | 2026-02-01 | Vir Biotechnology Inc | Preparations and methods for treating influenza a infection |
| US20230340083A1 (en) * | 2020-12-08 | 2023-10-26 | Vir Biotechnology, Inc. | Antibodies and methods for treatment of influenza a infection |
| CN112812095A (zh) * | 2021-01-29 | 2021-05-18 | 成都安满生物医药科技有限公司 | 一种巴洛沙韦酯中间体的合成方法 |
| WO2023201306A1 (en) | 2022-04-14 | 2023-10-19 | Invisishield Technologies Ltd. | Compositions for preventing or treating influenza infections |
| CN115777944B (zh) * | 2023-02-10 | 2023-05-12 | 北京衡美金叶营养健康科技有限公司 | 增强身体防御力的组合物及其制备方法和应用 |
| IL325937A (en) * | 2023-07-24 | 2026-03-01 | Univ Miami | AAV-delivered antibodies and methods of using them |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004076677A2 (en) | 2003-02-26 | 2004-09-10 | Institute For Research In Biomedicine | Monoclonal antibody production by ebv transformation of b cells |
| US8802820B2 (en) * | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| BRPI0914092B1 (pt) | 2008-10-22 | 2021-08-31 | Institute For Research In Biomedicine | Método de produção de um anticorpo a partir de células plasmáticas, método de produção de um anticorpo monoclonal a partir de células plasmáticas e método de produção de um anticorpo ou de um fragmento de anticorpo |
| US8326547B2 (en) | 2009-10-07 | 2012-12-04 | Nanjingjinsirui Science & Technology Biology Corp. | Method of sequence optimization for improved recombinant protein expression using a particle swarm optimization algorithm |
| EP2638072A4 (en) | 2010-11-12 | 2014-05-07 | Univ Rockefeller | FUSION PROTEINS FOR HIV THERAPY |
| JP6396313B2 (ja) | 2012-12-07 | 2018-09-26 | ファイザー・インク | 操作された単量体抗体断片 |
| EP3733244A1 (en) | 2013-10-02 | 2020-11-04 | Medlmmune, LLC | Neutralizing anti-influenza a antibodies and uses thereof |
| WO2017123685A1 (en) | 2016-01-13 | 2017-07-20 | Medimmune, Llc | Method of treating influenza a |
-
2019
- 2019-04-30 WO PCT/EP2019/061134 patent/WO2020221450A1/en not_active Ceased
-
2020
- 2020-03-04 TW TW109107093A patent/TW202106707A/zh unknown
- 2020-04-30 JP JP2021562803A patent/JP7719725B2/ja active Active
- 2020-04-30 WO PCT/EP2020/062160 patent/WO2020221908A1/en not_active Ceased
- 2020-04-30 CN CN202080034142.3A patent/CN114269381A/zh active Pending
- 2020-04-30 EP EP20721638.3A patent/EP3962530A1/en active Pending
- 2020-04-30 CA CA3132536A patent/CA3132536A1/en active Pending
- 2020-04-30 CN CN202411518877.XA patent/CN119192357A/zh active Pending
- 2020-04-30 KR KR1020217038260A patent/KR20220003000A/ko active Pending
- 2020-04-30 AU AU2020265407A patent/AU2020265407B2/en active Active
- 2020-04-30 SG SG11202109683TA patent/SG11202109683TA/en unknown
- 2020-04-30 BR BR112021018409A patent/BR112021018409A2/pt unknown
- 2020-04-30 EA EA202192923A patent/EA202192923A1/ru unknown
- 2020-04-30 US US17/607,383 patent/US20220226470A1/en active Pending
- 2020-04-30 MX MX2021012984A patent/MX2021012984A/es unknown
- 2020-04-30 PH PH1/2021/552176A patent/PH12021552176A1/en unknown
-
2021
- 2021-09-24 CO CONC2021/0012583A patent/CO2021012583A2/es unknown
- 2021-10-20 IL IL287423A patent/IL287423A/en unknown
- 2021-10-26 CL CL2021002807A patent/CL2021002807A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3962530A1 (en) | 2022-03-09 |
| WO2020221450A1 (en) | 2020-11-05 |
| PH12021552176A1 (en) | 2022-09-12 |
| CO2021012583A2 (es) | 2021-10-20 |
| CA3132536A1 (en) | 2020-11-05 |
| CL2021002807A1 (es) | 2022-08-19 |
| JP7719725B2 (ja) | 2025-08-06 |
| AU2020265407A1 (en) | 2021-10-07 |
| CN114269381A (zh) | 2022-04-01 |
| US20220226470A1 (en) | 2022-07-21 |
| AU2020265407B2 (en) | 2026-01-08 |
| TW202106707A (zh) | 2021-02-16 |
| KR20220003000A (ko) | 2022-01-07 |
| SG11202109683TA (en) | 2021-11-29 |
| BR112021018409A2 (pt) | 2021-11-23 |
| MX2021012984A (es) | 2021-12-10 |
| CN119192357A (zh) | 2024-12-27 |
| IL287423A (en) | 2021-12-01 |
| WO2020221908A1 (en) | 2020-11-05 |
| JP2022531556A (ja) | 2022-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202192923A1 (ru) | Антитела и способы лечения инфекции, вызываемой вирусом гриппа а | |
| CY1124756T1 (el) | Εξουδετερωτικα αντισωματα του ιου ανθρωπινης ανοσοανεπαρκειας | |
| MX2024006462A (es) | Anticuerpos anti-tmprss2 y fragmentos de union a antigeno. | |
| EP3996716C0 (en) | COMPOUNDS USED TO TREAT INFECTIONS CAUSED BY THE INFLUENZA VIRUS | |
| MX392098B (es) | Anticuerpos neutralizantes de poliomavirus. | |
| EA201991862A1 (ru) | Композиции и способы, предназначенные для лечения гемоглобинопатий | |
| EA201790630A1 (ru) | Способы получения рибозидов | |
| EA202090720A1 (ru) | ПРОИЗВОДНЫЕ GalNAc | |
| MX352338B (es) | Anticuerpos neutralizantes del virus de la influenza a y usos de estos. | |
| EA201791086A1 (ru) | Человеческие антитела против гемагглютинина вируса гриппа | |
| EA201791735A1 (ru) | Связывающие молекулы, направленные против гемагглютинина вируса гриппа, и пути их применения | |
| EA201791886A1 (ru) | Антивирусные соединения | |
| EA202190810A1 (ru) | Способы и наборы для получения цельной крови с инактивированным патогеном | |
| PH12021550521A1 (en) | Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof | |
| CU24580B1 (es) | Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas | |
| PL439808A1 (pl) | Sposoby i kompozycje hodowli komórkowych do produkcji przeciwciał | |
| EA202091769A1 (ru) | Вакцины против вируса гриппа и пути их применения | |
| MX2022009476A (es) | Anticuerpos anti-tmprss2 y fragmentos de union a antigeno. | |
| MX2024006295A (es) | Anticuerpos monoclonales de adn dirigidos al virus de la influenza. | |
| CL2017003309A1 (es) | Métodos de purificación y/o inactivación viral | |
| AR105541A1 (es) | ANTICUERPOS MONOCLONALES ESPECÍFICOS PARA EL ANTÍGENO P DEL VIRUS RESPIRATORIO SINCICIAL HUMANO (VRSh), PRODUCIDOS Y SECRETADOS POR HIBRIDOMAS CELULARES, ÚTILES PARA LA DETECCIÓN Y EL DIAGNÓSTICO DE LA INFECCIÓN CAUSADA POR VRSh | |
| EA201890187A1 (ru) | Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита | |
| MX2020004151A (es) | Detergentes compatibles con el medio ambiente para la inactivacion de virus envueltos en lipidos. | |
| EA202092675A1 (ru) | Фармацевтические комбинации | |
| WO2019209974A3 (en) | Potent zika virus-specific and cross-neutralizing monoclonal antibodies to zika and dengue viruses following zikv infection or vaccination |